Quinolinic Acid: An Endogenous Neurotoxin with Multiple Targets
Open accessThe DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Abstract
Quinolinic acid (QUIN), a neuroactive metabolite of the kynurenine pathway, is normally presented in nanomolar concentrations in human brain and cerebrospinal fluid (CSF) and is often implicated in the pathogenesis of a variety of human neurological diseases. QUIN is an agonist of N-methyl-D-aspartate (NMDA) receptor, and it has a high in vivo potency as an excitotoxin. In fact, although QUIN has an uptake system, its neuronal degradation enzyme is rapidly saturated, and the rest of extracellular QUIN can continue stimulating the NMDA receptor. However, its toxicity cannot be fully explained by its activation of NMDA receptors it is likely that additional mechanisms may also be involved. In this review we describe some of the most relevant targets of QUIN neurotoxicity which involves presynaptic receptors, energetic dysfunction, oxidative stress, transcription factors, cytoskeletal disruption, behavior alterations, and cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, QUIN increases the release and blocks the reuptake of glutamate in astrocytes, thus increasing glutamatergic extracellular concentrations (132).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [132]
In the citing paper
“Together, this pathway may trigger hippocampal and mPFC cellular damage and volume reductions (138,144,145).”
From The Impact of Stress and Major Depressive Disorder on Hippocampal and Medial Prefrontal Cortex Morphology (2019) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543 · cited 1×
“Areas of the brain most sensitive to QUIN neurotoxicity are the hippocampus and striatum [32] in which the NMDA receptors are widely distributed [33].”
BackgroundReplication of the neurochemical characteristics of Huntington's disease by quinolinic acid
Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., & Martin, J. B. (1986) · Nature · doi:10.1038/321168a0 · Cited by 1,286
Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Cytokines and endothelial cell biology
Pober, J. S., & Cotran, R. S. (1990) · Physiological Reviews · doi:10.1152/physrev.1990.70.2.427 · Cited by 1,242 · cited 1×
“Although TNF-α is not neurotoxic itself, this proinflammatory cytokine can contribute to neuronal damage through a variety of effects, such as stimulation of free radical formation, induction of cellular adhesion molecule expression, or potentiation of glutamatemediate neurotoxicity [123, 124].”
BackgroundNeuropharmacology of quinolinic and kynurenic acids.
Stone, T. W. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00441-7 · Cited by 948 · cited 3×
“Furthermore, 3-HAO activity may normally be restrained by factors such as the availability of Fe ions [8, 22, 23].”
BackgroundSchulze-Osthoff, K., Bakker, A. C., Vanhaesebroeck, B., Beyaert, R., Jacob, W. A., & Fiers, W. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42768-8 · Cited by 939
Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Stone, T. W., & Perkins, M. N. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90587-2 · Cited by 751 · cited 2×
“In 1981, Stone and Perkins discovered that QUIN was a potent excitant of neurons in the CNS, by acting as an agonist at the N-methyl-D-aspartate (NMDA) sensitive population glutamate receptors [29], and Schwarcz and coworkers (1983) were the first who demonstrated that QUIN causes selective neuronal lesions, and they…”
BackgroundKynurenine Pathway Metabolites in Humans: Disease and Healthy States
Chen, Y., & Guillemin, G. J. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2097 · Cited by 628 · cited 1×
“8 nmol/g wet weight; almost 2-fold than that found in the hippocampus (1 nmol/g wet weight) [16–18].”
BackgroundSteiner, J., Walter, M., Gos, T., Guillemin, G. J., Bernstein, H.-G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., zu Schwabedissen, L., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-94 · Cited by 568
Guillemin, G. J., Smythe, G., Takikawa, O., & Brew, B. J. (2005) · Glia · doi:10.1002/glia.20090 · Cited by 497 · cited 3×
“As shown previously in cortical neurons, dopaminergic neurons do not produce QUIN but take it up from the microenvironment [15, 40].”
Background
Research works printed but not linked: 1
- Blanco-Ayala T Serratos-Alvarez I Orozco-Ibarra M Effect of some kynurenines under succinate deshidrogenase activity and ATP production: in vitro experimental and computational tools Neuroscience Meeting 2012 60.09 New Orleans, LA, USA Society for Neuroscience
Cited by
Items 101–200 of 426
Ferreira, F. S., Biasibetti, H., Pierozan, P., Schmitz, F., Bertó, C. G., Prezzi, C. A., Manfredini, V., & Wyse, Â. T. D. S. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1003-2 · Cited by 54
Reactive Species in Huntington Disease: Are They Really the Radicals You Want to Catch?
Bono-Yagüe, J., Gómez-Escribano, A. P., Millán, J. M., & Vázquez‐Manrique, R. P. (2020) · Antioxidants · doi:10.3390/antiox9070577 · Cited by 55
Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis
Lee, J., Tan, V. X., Lovejoy, D. B., Braidy, N., Rowe, D. B., Brew, B. J., & Guillemin, G. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.011 · Cited by 52
Ciapała, K., Mika, J., & Rojewska, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011055 · Cited by 52
“Indeed, both substances reduced the mechanical and thermal hypersensitivity evoked by nerve injury, and a biochemical analysis indicated that Ro61–6048 reduced the levels of CD40/IBA1, IL-1β, IL-6, and NOS2 mRNA and/or proteins in both the spinal cord and DRG [21].”
BackgroundInfluentialThe Microbiota-Gut Axis in Premature Infants: Physio-Pathological Implications
Bresesti, I., Salvatore, S., Valetti, G., Baj, A., Giaroni, C., & Agosti, M. A. (2022) · Cells · doi:10.3390/cells11030379 · Cited by 57
“The diversion of tryptophan metabolism from 5-HT towards the kynurenine pathway may favor the manifestation of psychiatric disorders, such as anxiety and major depression [88].”
BackgroundA unified model of the biology of peripartum depression
Levin, G., & Ein‐Dor, T. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02439-w · Cited by 53
“However, by itself, QUIN is a neuroactive agonist of glutamate’s Nmethyl-D-aspartate receptor (NMDAR) that incurs neurotoxic effects via at least nine processes (reviewed in [33]) such as generation of reactive oxygen species (ROS), disruption of the blood-brain barrier, and destabilization of the cellular cytoskeleto…”
BackgroundBoros, F. A., Bohár, Z., & Vécsei, L. (2018) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2018.03.001 · Cited by 55
Knapskog, A., Aksnes, M., Edwin, T. H., Ueland, P. M., Ulvik, A., Fang, E. F., Eldholm, R. S., Halaas, N. B., Saltvedt, I. T., Giil, L. M., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13162 · Cited by 51
Anderson, E., Fishbein, J. S., Hong, J., Roeser, J., Furie, R. A., Aranow, C. B., Volpe, B. T., Diamond, B., & Mackay, M. C. (2021) · Lupus Science & Medicine · doi:10.1136/lupus-2021-000559 · Cited by 51
Lee, B., Lee, S. M., Song, J. W., & Choi, J. W. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.009 · Cited by 49
Maya, S., Prakash, T., & Goli, D. (2018) · NeuroToxicology · doi:10.1016/j.neuro.2018.06.015 · Cited by 49
Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
Yang, C., Nguyen, J., & Yen, Y. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00982-8 · Cited by 45
“Macrophages stimulated by IFN-α2 and IFN-γ could increase the production of quinolinic acid, an endogenous neurotoxin related to seizures and some neurologic disorders [95–97].”
BackgroundNeurotoxicity and Underlying Mechanisms of Endogenous Neurotoxins
Cao, Y., Li, B., Ismail, N., Smith, K. B., Li, T., Dai, R., & Deng, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312805 · Cited by 44
“biometabolic pathway can generate neuroactive compounds such as hydroxykynurenine (3‐HK) and quinolinic acid (QUIN/QA) [107].”
BackgroundSeminotti, B., Amaral, A. U., Ribeiro, R. T., Rodrigues, M. D. N., Colín-González, A. L., Leipnitz, G., Santamaría, A., & Wajner, M. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9548-9 · Cited by 43
Altered Tryptophan Catabolism in Placentas From Women With Pre-eclampsia
Keaton, S. A., Heilman, P. L., Bryleva, E. Y., Madaj, Z., Krzyżanowski, S., Grit, J. L., Miller, E. S., Jälmby, M., Kalapotharakos, G., Racicot, K. E., et al. (2019) · International Journal of Tryptophan Research · doi:10.1177/1178646919840321 · Cited by 44
Oboh, G., Ogunruku, O. O., Oyeleye, S. I., Olasehinde, T. A., Ademosun, A. O., & Boligon, A. A. (2016) · Journal of Dietary Supplements · doi:10.1080/19390211.2016.1237401 · Cited by 42
“Quinolinic acid (QA) is a neuroactive metabolite present in the brain and has been implicated in the pathogenesis of several neurodegenerative diseases via its ability to induce oxidative stress, behavioral disturbances, and neuronal cell death (Lugo-Huitron et al., 2013).”
BackgroundHu, P., Hunt, N. H., Arfuso, F., Shaw, L. C., Uddin, M. N., Zhu, M., Devasahayam, R. N., Adamson, S. J., Benson, V. L., Chan‐Ling, T., et al. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-21654 · Cited by 41
“Astrocyte dysfunction and gliotoxicity, blood–brain damage, and inflammation induced by QUIN also are implicated in its neurotoxicity.(11) Thus, activation of the KP in the CNS may damp down inflammatory processes but also damage neurons via the production of QUIN.”
BackgroundTryptophan metabolism and immune regulation in the human placenta
Silvano, A., Seravalli, V., Strambi, N., Cecchi, M., Tartarotti, E., Parenti, A., & Tommaso, M. D. (2021) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2021.103361 · Cited by 43
Xiao, W., Li, J., Gao, X., Yang, H., Su, J., Weng, R., Gao, Y., Ni, W., & Gu, Y. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114225 · Cited by 43
Zhang, K., He, L., Li, Z. B., Ding, R., Han, X., Chen, B., Cao, G., Ye, J.-H., Li, T., & Fu, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168835 · Cited by 42
Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design
Tanaka, M., Szatmári, I., & Vécsei, L. (2025) · Pharmaceuticals · doi:10.3390/ph18050607 · Cited by 29
Rose, M., Filiatreault, A., Guénette, J., Williams, A., & Thomson, E. M. (2020) · Environmental Research · doi:10.1016/j.envres.2020.109483 · Cited by 39
Lee, J. K., Liu, D., Jiang, D., Kulikowicz, E., Tekes, A., Liu, P., Qin, Q., Koehler, R. C., Aggarwal, M., Zhang, J., et al. (2021) · The Journal of Comparative Neurology · doi:10.1002/cne.25121 · Cited by 43
“QA is also involved in several human neurologic diseases, including autism, Alzheimer's disease, Huntington's disease, depression, and amyotrophic lateral sclerosis (Lugo-Huitrón et al., 2013).”
Thomsen, M. B., Jacobsen, J., Lillethorup, T. P., Schacht, A. C., Simonsen, M., Romero-Ramos, M., Brooks, D. J., & Landau, A. M. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20931140 · Cited by 38
“QA exerts neurotoxicity by increasing Ca flux into neurons via the NMDAion channels, disturbing the cytoskeleton, generating free radicals and oxidative stress and by causing lipid peroxidation.(29) Chronic exposure can cause structural changes affecting the microtubullar distribution and a decrease in organelles.”
BackgroundTerminalia chebula attenuates quinolinate-induced oxidative PC12 and OLN-93 cell death
Sadeghnia, H. R., Jamshidi, R., Afshari, A. R., Mollazadeh, H., Forouzanfar, F., & Rakhshandeh, H. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.03.012 · Cited by 38
The Energy Landscape of Human Serine Racemase
Raboni, S., Marchetti, M., Faggiano, S., Campanini, B., Bruno, S., Marchesani, F., Margiotta, M., & Mozzarelli, A. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00112 · Cited by 38
“Intermediates of the kynurenine pathway also bind the NMDA receptors: quinolinic acid is a strong agonist, whereas kynurenic acid acts as an antagonist (Németh et al., 2006; Lugo-Huitrón et al., 2013).”
BackgroundKynurenine Pathway Metabolites in the Blood and Cerebrospinal Fluid Are Associated with Human Aging
Solvang, S.-E. H., Hodge, A. M., Watne, L. O., Cabral-Marques, O., Nordrehaug, J. E., Giles, G. G., Dugué, P., Nygard, O. K., Ueland, P. M., McCann, A., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5019752 · Cited by 40
“Further, increasing basal concentrations of the NMDA receptor agonist QA, without a similar increase in the NMDAR antagonist KA, could be relevant for diseases where excitotoxicity is important such as neuro-degenerative disease [53].”
Foucault‐Fruchard, L., Doméné, A., Page, G., Windsor, M., Emond, P., Rodrigues, N., Dollé, F., Damont, A., Buron, F., Routier, S., et al. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.05.019 · Cited by 39
Dale, R. C., Thomas, T. G. S., Patel, S., Han, V. X., Kothur, K., Troedson, C., Gupta, S., Gill, D. S., Malone, S., Waak, M., et al. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51832 · Cited by 36
“QUIN is also an N-methyl-Daspartate receptor agonist and therefore neurotoxic.(22) 0 25 50 75 100”
Mishra, J., & Kumar, A. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.07.006 · Cited by 36
Koo, Y. S., Kim, H., Park, J. H., Kim, M. J., Shin, Y., Choi, B. T., Lee, S., & Shin, H. K. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2413841 · Cited by 38
“Although further studies are needed to better understand the underlying mechanisms, our findings improve the knowledge about IDO1 and IDO1-dependent neurotoxic kynurenine metabolites as possible regulators leading to the development of PSD. Future studies should be conducted not only on the manipulation of IDO1, QUIN,…”
BackgroundMethodInfluentialAlmulla, A. F., Supasitthumrong, T., Amrapala, A., Tunvirachaisakul, C., Jaleel, A.-K. K. A., Oxenkrug, G. F., Al‐Hakeim, H. K., & Maes, M. H. J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220295 · Cited by 38
Microbes and Monoamines: Potential Neuropsychiatric Consequences of Dysbiosis
Skolnick, S. D., & Greig, N. H. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.005 · Cited by 38
Pierozan, P., Biasibetti, H., Schmitz, F., Ávila, H., Parisi, M. M., Barbé‐Tuana, F. M., Wyse, Â. T. D. S., & Pessoa‐Pureur, R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.09.014 · Cited by 36
Lam, C. S., Li, J.-J., Tipoe, G. L., Youdim, M. B. H., & Fung, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177940 · Cited by 36
Self-Assembly and Multifaceted Bioactivity of a Silver(I) Quinolinate Coordination Polymer
Jaros, S. W., Krogul-Sobczak, A., Bażanów, B., Florek, M., Poradowski, D., Nesterov, D. S., Śliwińska-Hill, U., Kirillov, A. M., & Smoleński, P. (2021) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.1c02110 · Cited by 35
Ketamine – A New Antidepressant Drug with Anti-Inflammatory Properties
Jóźwiak-Bębenista, M., Sokołowska, P., Wiktorowska‐Owczarek, A., Kowalczyk, E., & Sienkiewicz, M. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001823 · Cited by 39
The gut–bone axis in osteoporosis: a multifaceted interaction with implications for bone health
Gu, C., Du, H., Li, N., Zhou, Y., Li, S., Sun, Y., Han, Y., Xu, X., & Li, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569152 · Cited by 34
Singh, S. V., Ganguly, R., Jaiswal, K., Yadav, A. K., Kumar, R., & Pandey, A. K. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i19.4458 · Cited by 33
Adedayo, B. C., Oyeleye, S. I., Okeke, B. M., & Oboh, G. (2020) · Flavour and Fragrance Journal · doi:10.1002/ffj.3615 · Cited by 33
Ferreira, F. S., Schmitz, F., Marques, E. P., Siebert, C., & Wyse, Â. T. D. S. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00192-2 · Cited by 34
Tryptophan, kynurenine pathway, and diabetic ketoacidosis in type 1 diabetes
Hoffman, W. H., Whelan, S. A., & Lee, N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254116 · Cited by 32
Jand, Y., Ghahremani, M. H., Ghanbari, A., Ejtemaei‐Mehr, S., Guillemin, G. J., & Ghazi‐Khansari, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-20164-0 · Cited by 33
Altered kynurenine pathway metabolism in patients with ankylosing spondylitis
Onmaz, D. E., Sivrikaya, A., Isik, K., Abuşoğlu, S., Gezer, İ. A., Yerlikaya, F. H., Abuşoğlu, G., Ünlü, A., & Tezcan, D. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108018 · Cited by 31
Trisal, A., Singh, I., Garg, G., Jorwal, K., & Singh, A. K. (2024) · 3 Biotech · doi:10.1007/s13205-024-04187-0 · Cited by 32
“While KA offers neuroprotection by inhibiting NMDA receptors, QA is neurotoxic, contributing to glutamate-induced damage (Lugo-Huitrón et al. 2013; Badawy 2017).”
Tumour brain: Pretreatment cognitive and affective disorders caused by peripheral cancers
Mampay, M., Flint, M. S., & Sheridan, G. K. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15571 · Cited by 32
“QUIN accumulation results in excitotoxicity, oxidative stress (via accumulation of ROS), neuronal cell death and disruption of glutamatergic neurotransmission (Lugo-Huitr on et al., 2013).”
BackgroundRole of the immune-kynurenine pathway in treatment-resistant schizophrenia
Chen, W., Tian, Y., Gou, M., Wang, L., Tong, J., Zhou, Y., Feng, W., Li, Y., Chen, S., Liu, Y., et al. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110926 · Cited by 30
Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design
Tanaka, M., Szatmári, I., & Vécsei, L. (2025) · doi:10.20944/preprints202503.2399.v1 · Cited by 30
Carpita, B., Nardi, B., Palego, L., Cremone, I. M., Massimetti, G., Carmassi, C., Betti, L., Giannaccini, G., & Dell’Osso, L. (2022) · CNS Spectrums · doi:10.1017/s1092852922000840 · Cited by 31
“QA is an agonist of NMDA, kainate, and α-7 nicotinic acetyl choline receptors, and it is apparently capable of activating specific types of NMDA receptors in the striatum and the hippocampus: thus, its elevation may lead to altered glutamate transmission, which was reported in many inflammatory CNS diseases.(47) QA, a…”
Schwarz, C., Mathieu, J., Gomez, J. A. L., Miller, M. R., Tikhonova, M., Nagaraja, T. G., & Alvarez, P. J. J. (2023) · Journal of Animal Science · doi:10.1093/jas/skad130 · Cited by 30
Majewski, M. S., Kasica, N., Jakimiuk, A., & Podlasz, P. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.01.004 · Cited by 29
“3-hydroxy-kynurenine (3-OH-kyn) and 3-hydroxy-anthranilic acid (3-OH-AA) are known because of their neurotoxic properties through oxygen radical generation; whereas, quinolinic acid (QUIN) toxicity is a result of NMDA receptor agonist activity (Lugo-Huitrón et al., 2013; Reyes-Ocampo et al., 2014).”
BackgroundHuang, J. Y., Larose, T. L., Luu, H. N., Wang, R., Fanidi, A., Alcala, K., Stevens, V. L., Weinstein, S. J., Albanes, D., Caporaso, N. E., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32555 · Cited by 31
“QA, a downstreammetabolite of kynurenine, is a known neurotoxin via stimulation of the presynaptic receptor which induces oxidative stress and enhances the production of proinflammatory cytokines in the brain.(41) In the current study, circulating QA concentrations were highly correlated with KTR (r = 0.”
BackgroundSummers, B. S., Broome, S. T., Pang, T. W. R., Mundell, H. D., Belic, N. K., Tom, N., Ng, M. L., Yap, M. L., Sen, M. K., Sedaghat, S., et al. (2024) · International Journal of Tryptophan Research · doi:10.1177/11786469241248287 · Cited by 30
“…metabolised by resident cells, or as described above, KP metabolites for example KYN and 3-HK also enter tissues while QUIN is blocked from getting across the BBB. 59 As per Figure 1, TRP metabolites segregate into one of 2 categories – neuroprotective (KYNA, PIC) or neurotoxic (QUIN, 3-HK).”
BackgroundThe Kynurenine Pathway, Aryl Hydrocarbon Receptor, and Alzheimer’s Disease
Cortés-Malagón, E. M., Ornelas, A. L., Olvera‐Gómez, I., & Bonilla‐Delgado, J. (2024) · Brain Sciences · doi:10.3390/brainsci14090950 · Cited by 28
Bhat, A., Tan, V. X., Heng, B., Lovejoy, D. B., Sakharkar, M. K., Essa, M. M., Chidambaram, S. B., & Guillemin, G. J. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00636 · Cited by 29
AGE/Non-AGE Glycation: An Important Event in Rheumatoid Arthritis Pathophysiology
Monu, M., Agnihotri, P., & Biswas, S. (2021) · Inflammation · doi:10.1007/s10753-021-01589-7 · Cited by 28
“Quinolinic acid (QA) is a metabolite synthesis in the kynurenine pathway, majorly involved in neurotoxicity and inflammation due to binding affinity with RAGE at VC1 domain [113].”
BackgroundPierozan, P., Biasibetti, H., Schmitz, F., Ferreira, F. S., Netto, C. A., & Wyse, Â. T. D. S. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9834-6 · Cited by 29
“In addition, it has been shown that QUIN and Hcy are involved in energy and redox status changes (Lugo-Huitron et al. 2013; Staehelin 2005),”
BackgroundPierozan, P., Fernandes, C. G., Dutra, M. F., Pandolfo, P., Ferreira, F. S., de Lima, B. O., Porciúncula, L. O., Wajner, M., & Pessoa‐Pureur, R. (2014) · FEBS Journal · doi:10.1111/febs.12762 · Cited by 30
Karakawa, S., Nishimoto, R., Harada, M., Arashida, N., & NAKAYAMA, A. (2019) · Chromatography · doi:10.15583/jpchrom.2019.010 · Cited by 27
Zhao, J., Bai, X., Du, J., Chen, Y., Guo, X., Zhang, J., Gan, J., Wu, P., Chen, S., Zhang, X., et al. (2025) · Oncology Reports · doi:10.3892/or.2025.8919 · Cited by 29
“The Trp metabolite 5‑HT can modulate the function of tumor‑infiltrating macrophages by regulating the expression of matrix metalloproteinase 12, which influences tumor angio‑ genesis.”
Zhang, S., Collier, M. E. W., Heyes, D. J., Giorgini, F., & Scrutton, N. S. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108702 · Cited by 26
“Since KMO has the tightest binding affinity for L-KYN under normal conditions, the KMO branch has been considered to be the major metabolic route of the KP [18, 19].”
BackgroundAnderson, E., Jin, Y., Shih, A., Arazi, A., Goodwin, S., Roeser, J., Furie, R. A., Aranow, C. B., Volpe, B. T., Diamond, B., et al. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2022-000808 · Cited by 26
HNF4α mediated QPRT expression in the kidney facilitates resilience against acute kidney injury
Clark, A. J., Saadé, M. C., Vemireddy, V., Vu, K. Q., Flores, B. M., Etzrodt, V., Ciampa, E. J., Huang, H., Takakura, A., Zandi‐Nejad, K., et al. (2023) · Kidney International · doi:10.1016/j.kint.2023.09.013 · Cited by 26
The roles of the kynurenine pathway in COVID-19 neuropathogenesis
Dehhaghi, M., Heydari, M., Panahi, H. K. S., Lewin, S. R., Heng, B., Brew, B. J., & Guillemin, G. J. (2024) · Infection · doi:10.1007/s15010-024-02293-y · Cited by 27
Aberrant self-grooming as early marker of motor dysfunction in a rat model of Huntington's disease
Tartaglione, A. M., Armida, M., Potenza, R. L., Pèzzola, A., Popoli, P., & Calamandrei, G. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.058 · Cited by 25
Verheyen, N., Meinitzer, A., Grübler, M. R., Ablasser, K., Kolesnik, E., Fahrleitner‐Pammer, A., Belyavskiy, E., Trummer, C., Theiler‐Schwetz, V., Pieske‐Kraigher, E., et al. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-1159 · Cited by 25
“Via promoting oxidative stress, also QUIN has been shown to induce cell death [9, 10].”
BackgroundKanchanatawan, B., Sirivichayakul, S., Carvalho, A. F., Anderson, G., Gałecki, P., & Maes, M. H. J. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.033 · Cited by 26
Quinolinic acid potentially links kidney injury to brain toxicity
Saliba, A., Debnath, S., Tamayo, I. M., Lee, H. J., Ragi, N., Das, F., Montellano, R., Tůmová, J., Maddox, M., Trevino, E., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.180229 · Cited by 24
“QA interacts with NMDA receptors, competing with glutamate, and contributes to excitotoxicity and neuronal damage (23, 48–51).”
Arora, M. K., Ratra, A., Asdaq, S. M. B., Alshamrani, A. A., Alsalman, A. J., Kamal, M., Tomar, R., Sahoo, J., Jangra, A., & Imran, M. (2022) · Molecules · doi:10.3390/molecules27061834 · Cited by 24
Nagy-Grócz, G., Spekker, E., & Vécsei, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031698 · Cited by 24
“Different from KYNA, QUIN is an endogenous glutamate receptor agonist, which when produced by microglia [26], can provoke lipid peroxidation [27] and has a relevant role in the neurodegenerative process [28].”
BackgroundKubicová, L., Hadaček, F., Weckwerth, W., & Chobot, V. (2015) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2015.01.030 · Cited by 24
Kynurenines and Neurofilament Light Chain in Multiple Sclerosis
Pukoli, D., Polyák, H., Rajda, C., & Vécsei, L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.658202 · Cited by 26
“, 2010): during neuroinflammation, activated microglia and QUIN produced by macrophages can enhance–via the activation of the NMDA receptor–the activity of NOS enzyme activity in astrocytes and neurons resulting in enhanced nitric oxide (NO) production [see review (Lugo-Huitrón et al., 2013)].”
BackgroundHigazi, A., Kamel, H., Abdelnaem, E. A., Abdullah, N. M., Mahrous, D. M., & Osman, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-86162-w · Cited by 24
Capillary electrochromatography-mass spectrometry of kynurenine pathway metabolites
Chawdhury, A. S. M. M. R., Shamsi, S. A., Miller, A. H., & Liu, A. (2021) · Journal of Chromatography A · doi:10.1016/j.chroma.2021.462294 · Cited by 23
Triphenyl phosphate disrupts placental tryptophan metabolism by activating MAOA/ROS/NFκB
Lu, X., Hong, J., Zhang, J., Liu, Q., Liao, G., Shi, Y., Tang, H., & Liu, X. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.166688 · Cited by 23
Chilosi, M., Doglioni, C., Ravaglia, C., Martignoni, G., Salvagno, G. L., Pizzolo, G., Bronte, V., & Poletti, V. E. (2022) · Biomedicines · doi:10.3390/biomedicines10061332 · Cited by 23
Chávez-Castillo, M., Nava, M., Ortega, Á., Rojas, M., Núñez, V., Salazar, J. J., Bermúdez, V., & Rojas, J. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200413144401 · Cited by 24
“In addition, the metabolism of kynurenine yields quinolinic acid and kynurenic acid (KA), both of which promote excitotoxicity by binding to NMDA receptors and promoting glutamate release in glial cells [58].”
BackgroundO'Brien, N. F., Fonseca, Y., Johnson, H. C., Postels, D. G., Birbeck, G. L., Chimalizeni, Y. F., Seydel, K. B., Gushu, M. B., Phiri, T., June, S., et al. (2022) · Malaria Journal · doi:10.1186/s12936-022-04163-0 · Cited by 21
“Pulse pressure (mmHg), median [IQR] 40 [35, 45]”
Curran, C. S., & Kopp, J. B. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04584-8 · Cited by 22
“Because quinolinate is also a neurotoxin [117], understanding QPRT regulatory networks may provide further insight into NAD depletion and neurological complications that can develop in CKD [118] (Fig.”
BackgroundThe Mystery of Chemotherapy Brain: Kynurenines, Tubulin and Biophoton Release
Sordillo, P. P., & Sordillo, L. A. (2020) · Anticancer Research · doi:10.21873/anticanres.14061 · Cited by 22
Modulation of the Nitric Oxide/BH4 Pathway Protects Against Irradiation-Induced Neuronal Damage
Thabet, N. M., Rashed, E. R., Abdel-Rafei, M. K., & Moustafa, E. M. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03306-0 · Cited by 20
States of quinolinic acid excess in urine: A systematic review of human studies
Saadé, M. C., Clark, A. J., & Parikh, S. M. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1070435 · Cited by 22
Implications of metabolism on multi‐systems healthy aging across the lifespan
Yao, S., Colangelo, L. A., Perry, A., Marron, M. M., Yaffe, K. S., Sedaghat, S., Lima, J. A. C., Tian, Q., Clish, C. B., Newman, A. B., et al. (2024) · Aging Cell · doi:10.1111/acel.14090 · Cited by 20
Singh, P. N. D., Mishra, G., Molla, M., Yimer, Y. S., Zewdu, W. S., Ferede, Y. A., & Ewunetie, A. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105047 · Cited by 22
Bravi, B., Verga, C., Palladini, M., Sara, P., Camilla, B., Sut, S., Dall’Acqua, S., Colombo, C., Comai, S., & Benedetti, F. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.01.025 · Cited by 19
Gelpi, M., Ueland, P. M., Trøseid, M., Mocroft, A., Lebech, A., Ullum, H., Midttun, Ø., Lundgren, J. D., & Nielsen, S. D. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz465 · Cited by 21
Chen, Y., Zhou, Y., Laborda, P., Wang, H., Wang, R., Chen, X., Liu, F., Yang, D., Wang, S., Shi, X., et al. (2021) · Pest Management Science · doi:10.1002/ps.6495 · Cited by 19
Marques, N. F., Stefanello, S. T., Froeder, A. L. F., Busanello, A., Boligon, A. A., Athayde, M. L., Soares, F. A. A., & Fachinetto, R. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1582-5 · Cited by 20
“The activation of NMDA receptor leads to an increase in intracellular Ca concentration, leading to ATP depletion, mitochondrial dysfunction, oxidative stress and cell damage [24].”
BackgroundGalley, J. D., Rajasekera, T. A., Bennouna, D., Batabyal, A., Verosky, B. G., Woodke, S. T., Stokes, J., Brown, A. K., Murthy, S., Kopec, R. E., et al. (2024) · Beneficial Microbes · doi:10.1163/18762891-bja00047 · Cited by 18
Hydrogen sulfide reduces oxidative stress in Huntington’s disease via Nrf2
Jiang, Z., Liu, D., Li, T., Gai, C., Xin, D., Zhao, Y., Song, Y., Cheng, Y., Li, T., & Wang, Z. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01051 · Cited by 18
“Then, we assessed MMP via JC-1, with a transition Lugo-Huitrón et al., 2013; Loganathan and Thayumanavan, 2018).”
Kynurenines and Mitochondrial Disturbances in Multiple Sclerosis
Pukoli, D., & Vécsei, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115098 · Cited by 19
Oliveros, A., Wininger, K. M., Sens, J. P., Larsson, M. K., Liu, X. C., Choi, S., Faka, A., Schwieler, L., Engberg, G., Erhardt, S., et al. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.09.010 · Cited by 20
“Interestingly, the kynurenine pathway also produces the excitotoxic N-Methyl-D-Aspartate receptor (NMDAR) agonist quinolinic acid (QUIN), which has been shown to be elevated in the CSF of suicide attempters (Brundin et al., 2016; Erhardt et al., 2013; Lugo-Huitron et al., 2013).”
BackgroundCytoskeleton as a Target of Quinolinic Acid Neurotoxicity: Insight from Animal Models
Pierozan, P., & Pessoa‐Pureur, R. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0654-8 · Cited by 20
“The neurotoxicity of QUIN results from complex mechanisms including activation of presynaptic receptors, energetic dysfunction, oxidative stress, transcription factors, and behavioral impairments [3, 4].”
BackgroundBiochemical and dietary functions of tryptophan and its metabolites in human health
Nayak, B. N., Singh, R. B., & Buttar, H. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819815-5.00003-3 · Cited by 24
Bao, C., Huang, J., Wu, H., Ma, Y., Zhou, H., Chen, L., Yang, D., Liu, H., Shi, Y., & Lu, Y. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1019590 · Cited by 18
“Moreover, quinolinate phosphoribosyl transferase (QPRT) activity is low in the hippocampus, and QUIN is difficult to metabolize in the hippocampus; therefore, the neurotoxicity of QUIN is most likely to affect the hippocampus (Lugo-Huitron et al., 2013).”
BackgroundHeimberger, A. B., & Lukas, R. V. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164577 · Cited by 17
“Previous work has additionally shown that the injection of QA in the brains of animals induces hyperactive behavior and impairs memory (7).”
BackgroundGalantamine-Memantine Combination in the Treatment of Parkinson’s Disease Dementia
Frost, E. D., Shi, S. X., Byroju, V. V., Rissardo, J. P., Donlon, J., Vigilante, N. F., Murray, B. P., Walker, I. M., McGarry, A. J., Ferraro, T. N., et al. (2024) · Brain Sciences · doi:10.3390/brainsci14121163 · Cited by 17
Jang, S., & Park, S.-H. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.1.24 · Cited by 17
“In the brain, QUIN is found in activated microglia and brain inflammation increases the QUIN levels in brain tissues and extracellular fluids.(3) Proinflammatory mediators like interferon-γ, beta amyloid (Aβ), tumor necrosis factor α, and platelet activating factors reportedly induce QUIN overproduction within activat…”
BackgroundBo, L., Guojun, T., & Guo, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01363 · Cited by 19
“The biologically active metabolites of KP mainly included Kyn and its decomposition products such as neuroprotective kynurenic acid (KYNA) (64), neurotoxic 3-hydroxy-L-kynurenine (3-OH-KYN) and its downstream enzyme metabolites, 3-hydroxyanthranilic acid (3HAA) (65), the excitotoxin, and N-methyl-d-aspartate (NMDA) re…”
BackgroundCannabinoids: Glutamatergic Transmission and Kynurenines
Colín-González, A. L., Aguilera, G., & Santamaría, A. (2016) · Advances in neurobiology · doi:10.1007/978-3-319-28383-8_10 · Cited by 17
Metadata
- Authors
- Lugo-Huitrón, R., Ugalde Muñiz, P., Pineda, B., Pedraza-Chaverrí, J., Ríos, C., & Pérez-de la Cruz, V.
- Affiliations
- Instituto Nacional de Neurología y Neurocirugía (MX)
- Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Insurgentes Sur 3877, S.S.A., 14269 México, DF, Mexico
- Laboratorio de Neuroinmunología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Insurgentes Sur 3877, S.S.A., 14269 México, DF, Mexico
- Departamento de Biología, Facultad de Química, Universidad Nacional Autónoma de México, 04510 México, DF, Mexico
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-14
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- PMC
- PMC3780648
- OpenAlex
- W1991576487
- Cited by
- 394
- References
- 146
- Citations by year
- 2026: 44 · 2025: 48 · 2024: 50 · 2023: 41 · 2022: 54 · 2021: 42 · 2020: 23 · 2019: 17 · 2018: 16 · 2017: 23 · 2016: 21 · 2015: 11 · 2014: 4
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Oxidative Medicine and Cellular Longevity (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Consejo Nacional de Ciencia y Tecnología (183867)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- quinolinic acid, kynurenine pathway, neurotoxicity, excitotoxicity, presynaptic receptors, oxidative stress, transcription factors, cytoskeleton disruption, behavioral alterations, neuronal cell death, neurological disorders
- MeSH terms
- Animals, Energy Metabolism, Humans, Inflammation, Neurotoxins, Quinolinic Acid, Oxidative Stress, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.